Showing 3131-3140 of 7283 results for "".
- Nevisense Boosts Clinician Confidence in Early Melanoma Diagnosishttps://practicaldermatology.com/news/nevisense-boosts-clinicians-confidence-in-early-melanoma-diagnosis/2461053/Nevisense provides valuable diagnostic guidance for clinicans when evaluating atypical pigmented skin lesions, according to a new study. The Nevisense method uses small electrical impulses to detect cellular irregularities beneath the skin’s surface. In the pilot study,
- Vial Connects with Advisory Board at 2022 Maui Dermatology Conferencehttps://practicaldermatology.com/news/vial-connects-with-advisory-board-at-2022-maui-dermatology-conference/2461050/Vial, in conjunction with the 2022 Maui Dermatology Conference, is hosting an Advisory Board co-hosted by Leon Kircik, MD, FAAD. Dr. Kircik and Vial, along with leading research sites, will discuss and collaborate on how Vial can continue to help grow dermatology research sites and tackle the big
- Survey Reveals Impact of AGA on Affected Men, Interest in New Therapieshttps://practicaldermatology.com/news/survey-reveals-impact-of-aga-on-affected-men-interest-in-new-therapies/2461046/Nearly two-thirds (64%) of men with androgentic alopecia (AGA) say the condition has a negative affect on their lives, yet more than half (56%) have never sought treatment for the condition, results of a survey show. Findings from the survey, conducted on behalf of
- Scientis: Mikki Bey Crawford Named US VP and General Manager, Aesthetic Dermatologyhttps://practicaldermatology.com/news/scientis-mikki-bey-crawford-named-us-vp-and-general-manager-aesthetic-dermatology/2461045/Mikki Bey Crawford is now US Vice President and General Manager, Aesthetic Dermatology for Scientis. In her new role, she will lead the sales and marketing teams to accelerate the growth of Cyspera® in the US. "We are so pleased t
- FDA Approves Pfizer's Cibinqo for Moderate-to-Severe AD in Adultshttps://practicaldermatology.com/news/fda-approves-pfizers-cibinqo-for-moderate-to-severe-ad-in-adults/2461037/Pfizer's Cibinqo® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, is now FDA approved for the treatment of adults with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including bi
- FDA Approves Rinvoq for Adults and Children 12 Years and Older with Refractory, Moderate to Severe ADhttps://practicaldermatology.com/news/us-fda-approves-rinvoq-for-adults-and-children-12-years-and-older-with-refractory-moderate-to-severe-ad/2461036/The FDA has given its nod to AbbVie’s Rinvoq (upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including bio
- Scleroderma Research Foundation Announces $1.5M Matching Gift in Honor of Bob Sagethttps://practicaldermatology.com/news/scleroderma-research-foundation-announces-15m-matching-gift-in-honor-of-bob-saget/2461035/The Scleroderma Research Foundation (SRF) announced a $1.5M matching gift in honor of Bob Saget, a SRF
- Avita Medical's Spray-On Skin Cells Demonstrate Proof of Concept in Aging Skin and EBhttps://practicaldermatology.com/news/avita-medicals-spray-on-skin-cells-demonstrate-proof-of-concept-in-rejuvenation-and-eb/2461028/Preclinical data successfully established proof of concept for Avita Medical’s Spray-On Skin Cells in skin rejuvenation and epidermolysis bullosa (EB), the company reports. AVITA Medical’s first US product, the RECELL System, was approved by FDA in September 2018.
- Drug Combination Boosts Progression-free Survival in Advanced Melanomahttps://practicaldermatology.com/news/drug-combination-boosts-progression-free-survival-in-advanced-melanoma/2461027/Combining relatlimab and nivolumab (Opdivo) may double progression-free survival in patients with advanced melanoma, according to a new study in the New England Journal of Medicine. Relatlimab, which blocks
- Survey: Consumers Interested in Medical Cannabis Products for Inflammatory Skin Disordershttps://practicaldermatology.com/news/survey-consumers-interested-in-medical-cannabis-products-for-inflammatory-skin-disorders/2461025/Patients with dermatologic conditions are open to trying medical cannabis products (MCPs) as potential treatments, according to a new study from George Washington University (GW) School of Medicine and Health Sciences (SMHS) and University of Maryland researchers. “MCPs, which are